Synthetic Biologics to Participate in Maxim 2022 Virtual Growth Conference

Synthetic Biologics, Inc.

ROCKVILLE, Md., March 22, 2022 (GLOBE NEWSWIRE) — Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapies designed to address diseases in areas of high unmet need, today announced that the company’s management will provide a business update and participate in a panel discussion titled “Pancreatic Cancer: Turning the Tide for One of the Most Challenging Indications in Oncology” at the conference. Maxim 2022 on virtual growth, which will be held virtually from March 28 to March 30, 2022. .

Roundtable details include:

Title: “Pancreatic cancer: turning the tide for one of the most difficult indications in oncology”

Date: March 28, 2022

Time: 12:00 p.m. – 1:00 p.m. ET

The conference will be available via the M-Vest Portal for registered members.

About Synthetic Biologics, Inc.

Synthetic Biologics, Inc. (NYSE American: SYN) is a diversified clinical-stage company that develops therapeutic products designed to treat diseases in areas where the need remains unmet. The company recently completed the acquisition of VCN Biosciences, SL (VCN), which is developing a novel oncolytic adenovirus (OV) platform designed for intravenous (IV), intravitreal and antitumor administration to trigger tumor cell death , improve access to co-administered cancer therapies against the tumor and promote a robust anti-tumor response supported by the patient’s immune system. In addition, the Company’s lead candidates are: (1) SYN-004 (ribaxamase) which is designed to degrade certain IV beta-lactam antibiotics commonly used in the gastrointestinal (GI) tract to prevent (a) damage to the microbiome, (b) Clostridioides difficile (CDI), (c) overgrowth of pathogenic organisms, (d) emergence of antimicrobial resistance (AMR), and (e) acute graft versus host disease (aGVHD ) in allogeneic hematopoietic cell (HCT) transplant recipients, and (2) SYN-020, a recombinant oral formulation of the intestinal alkaline phosphatase (IAP) enzyme produced under cGMP conditions and intended to treat both diseases local gastrointestinal and systemic diseases. For more information, please visit the Synthetic Biologics website at

For more information, please contact:

Investor Relations:
Chris Calabrian
LifeSci Advisors, LLC
[email protected]

Previous This group of stocks is signaling a rebound, and that's good news for the S&P 500, according to the technical analyst
Next Markets live, Wednesday, March 23, 2022